• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[苯并咪唑治疗棘球蚴病的研究进展]

[Progress in researches of benzimidazole in treatment of echinococcosis].

作者信息

Wen-Jun Z, Xiu-Min H, Ya-Min G

机构信息

Graduate School of Qinghai University, Xining 810000, China.

出版信息

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2017 Jun 27;29(4):530-533. doi: 10.16250/j.32.1374.2017057.

DOI:10.16250/j.32.1374.2017057
PMID:29508601
Abstract

Echinococcosis is a severe zoonosis parasitic disease and mainly caused by the larvae of and . Because of the limitation of operation level, such as recurrence and death, the drug treatment is still the most important method in our country. Meanwhile, the annual number of drug treatments is far greater than surgical treatments. Drugs play a significant role in the preoperative reduction of lesions, reducing pain, extending the life of patients .This article reviews the status of animals treatment and clinical treatment of echinococcosis treated by the benzimidazole drugs and their new formulations, provides the basis for exploring the development direction of anti-echinococcosis drug treatment research.

摘要

棘球蚴病是一种严重的人畜共患寄生虫病,主要由棘球绦虫属幼虫引起。由于手术水平的限制,如复发和死亡等问题,药物治疗在我国仍然是最重要的方法。同时,每年药物治疗的数量远远大于手术治疗。药物在术前缩小病灶、减轻疼痛、延长患者生命方面发挥着重要作用。本文综述了苯并咪唑类药物及其新剂型治疗棘球蚴病的动物治疗和临床治疗现状,为探索抗棘球蚴病药物治疗研究的发展方向提供依据。

相似文献

1
[Progress in researches of benzimidazole in treatment of echinococcosis].[苯并咪唑治疗棘球蚴病的研究进展]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2017 Jun 27;29(4):530-533. doi: 10.16250/j.32.1374.2017057.
2
On the importance of targeting parasite stem cells in anti-echinococcosis drug development.靶向寄生虫干细胞在抗包虫病药物研发中的重要性
Parasite. 2014;21:72. doi: 10.1051/parasite/2014070. Epub 2014 Dec 22.
3
Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo.蛇床子素对细粒棘球绦虫的体外作用及对多房棘球绦虫的体内作用
Vet Parasitol. 2016 Aug 15;226:38-43. doi: 10.1016/j.vetpar.2016.05.016. Epub 2016 Jun 23.
4
Recent advances in Echinococcus genomics and stem cell research.棘球蚴基因组学与干细胞研究的最新进展。
Vet Parasitol. 2015 Oct 30;213(3-4):92-102. doi: 10.1016/j.vetpar.2015.07.031. Epub 2015 Jul 31.
5
[Advances in surgical operation treatment of hepatic echinococcosis].肝包虫病外科手术治疗进展
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2018 Feb 26;30(1):104-107. doi: 10.16250/j.32.1374.2017168.
6
Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus?用于治疗囊型和泡型棘球蚴病的苯并咪唑类药物:共识是什么?
Expert Rev Anti Infect Ther. 2009 Mar;7(2):145-9. doi: 10.1586/14787210.7.2.145.
7
Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis.苯并咪唑氨基甲酸盐治疗人体棘球蚴病的多中心临床试验。
Bull World Health Organ. 1986;64(3):383-8.
8
Combination chemotherapy of Echinococcus granulosus--in vitro studies.细粒棘球绦虫联合化疗——体外研究
Trans R Soc Trop Med Hyg. 1988;82(2):263-4. doi: 10.1016/0035-9203(88)90442-7.
9
Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis.泡型和囊型棘球蚴病的创新化疗治疗方案。
Parasitology. 2007 Nov;134(Pt 12):1657-70. doi: 10.1017/S0031182007003198. Epub 2007 Jul 16.
10
Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.人包虫病(囊型和泡型)的药物治疗进展:化合物和治疗靶点。
PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006422. doi: 10.1371/journal.pntd.0006422. eCollection 2018 Apr.

引用本文的文献

1
Synthetic rEg.P29 Peptides Induce Protective Immune Responses Against in Mice.合成的重组P29肽诱导小鼠针对[具体疾病或病原体,原文未明确]产生保护性免疫反应。
Vaccines (Basel). 2025 Mar 3;13(3):266. doi: 10.3390/vaccines13030266.
2
Prediction and identification of epitopes in the Echinococcus multilocularis thrombospondin 3 antigen.预测和鉴定细粒棘球蚴凝血酶敏感蛋白 3 抗原表位。
Technol Health Care. 2022;30(4):799-814. doi: 10.3233/THC-212983.